Results 91 to 100 of about 2,519 (184)

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Case Reports in Cardiology, 2017
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation.
Steven Song, Joselle Cook, Clive Goulbourne, Matthew Meade, Louis Salciccioli, Jason Lazar   +5 more
doaj   +1 more source

Direct oral anticoagulants: first airbag

Медицинский совет, 2019
The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj   +1 more source

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Journal of the American College of Cardiology, 2016
Idarucizumab is a specific reversal agent that rapidly neutralizes dabigatran’s anticoagulant activity [(1–3)][1]. We investigated restoration of dabigatran anticoagulation 24 h after idarucizumab treatment and the safety and effectiveness of a second idarucizumab treatment.
Stephan, Glund, Joachim, Stangier, Joanne, van Ryn, Michael, Schmohl, Viktoria, Moschetti, Wouter, Haazen, Marina, De Smet, Dietmar, Gansser, Stephen, Norris, Benjamin, Lang, Paul, Reilly, Jörg, Kreuzer   +11 more
openaire   +2 more sources

A dabigatran-antidótum, az intravénás idarucizumab első hazai alkalmazása | The first use of iv. idarucizumab for dabigatran reversal in Hungary [PDF]

, 2017
Absztrakt: Az új típusú, direkt orális antikoagulánsok közül jelenleg egyedül a direkt trombingátló dabigatran rendelkezik hatékony antidótummal.
Zoltán Szántó, Barabás, Éva, Gábor Bencsik, Éva Barabás, Szántó, Zoltán, Bencsik, Gábor, Ildikó Bodócs, Herr, György, László Pál, Lajos Driesz, Driesz, Lajos, György Herr, Pál, László, József Borbola, Bodócs, Ildikó, Borbola, József   +15 more
core   +1 more source

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran

Vascular Health and Risk Management, 2019
David Giannandrea,1,2,* Anna Mengoni,3,* Erberto Carluccio,3 Giuseppe Ambrosio31Neurology Departement - Stroke Unit, Gubbio/Gualdo Tadino Hospitals, Perugia, Italy; 2Association “Naso Sano”, Umbria Regional Registry of No-Profit Organization,
Giannandrea D, Mengoni A, Carluccio E, Ambrosio G   +3 more
doaj  

Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention

Российский кардиологический журнал, 2019
Reducing of cardiovascular risk, morbidity and mortality is considered as one of the main aims of modern cardiology, which should help increase life expectancy.
Yu. A. Karpov
doaj   +1 more source

The incidence of thrombotic events with idarucizumab and andexanet alfa : a systematic review and meta-analysis

, 2020
© 2020 Elsevier Ltd. All rights reserved.Introduction: Direct thrombin inhibitor, dabigatran and factor Xa inhibitors, apixaban, edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some indications.
Ferreira, Joaquim J, Rodrigues, André Oliveira, Costa, João, Caldeira, Daniel, Pinto, Fausto J., David, Cláudio   +5 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report

, 2017
Dabigatran, an oral direct thrombin inhibitor, is frequently used in treatment of venous thromboembolism and prevention of stroke in non-valvular atrial fibrillation.
Lene Rosenberg, Gustav Gerstrøm, Rosenberg, Lene, Nybo, Mads, Gerstrøm, Gustav, Mads Nybo   +5 more
core   +1 more source